Obesity Pharmacotherapy: Which Drug Actually Works Best?

The rising prevalence of obesity poses significant health risks worldwide, including in India. To address this, the American College of Physicians sponsored a living systematic review. This review evaluated the benefits and harms of various weight management options, focusing specifically on modern obesity pharmacotherapy. Consequently, researchers assessed sixty-nine trials containing over one hundred thousand participants.

Efficacy of Current Obesity Pharmacotherapy

The meta-analysis revealed that nearly all studied medications outperformed placebos. Specifically, semaglutide and tirzepatide demonstrated the most substantial weight loss outcomes. Furthermore, semaglutide probably reduces major adverse cardiovascular events and all-cause mortality. In contrast, tirzepatide showed superior results for weight reduction and quality of life improvements. However, direct head-to-head trials between these medications remain very limited.

Adverse Events and Discontinuation Rates

Despite these benefits, patient tolerability remains a crucial clinical concern. For example, many participants discontinued therapy due to adverse events. In particular, gastrointestinal side effects were highly common with GLP-1 receptor agonists. Consequently, physicians must carefully weigh these harms against the potential long-term benefits. Additionally, clinical evidence suggests that patients often regain weight after stopping these medications. Therefore, long-term or even lifelong treatment may be necessary to maintain therapeutic success.

Practice Implications for Clinicians

In clinical practice, selecting the right medication requires a personalized approach. For instance, clinicians should discuss costs, comorbidities, and patient preferences. Furthermore, certain drugs carry unique safety warnings that require attention. Specifically, phentermine-topiramate requires regular pregnancy testing, and clinicians should avoid it in patients with cardiovascular disease. Meanwhile, naltrexone-bupropion carries warnings regarding potential suicidality. Ultimately, the choice of therapy must align with the patient’s overall health profile and financial capacity.

Frequently Asked Questions

Q1: Which pharmacologic treatments for obesity showed the greatest weight loss?

In this systematic review, semaglutide and tirzepatide demonstrated the most substantial weight loss compared to other therapies.

Q2: What happens when patients discontinue these weight loss medications?

Consequently, significant weight regain commonly occurs after treatment discontinuation, which means long-term therapy is usually necessary.

Q3: Did any specific medication show a reduction in cardiovascular events?

Importantly, semaglutide probably reduced major adverse cardiovascular events and all-cause mortality, unlike other drugs in this review.

References

1. Damen JAA et al. Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2026 Jun 16. doi: 10.7326/ANNALS-24-03764. PMID: 42296503.
2. Qaseem A, Cross JT Jr, Harrod CS, et al. Pharmacologic treatments with lifestyle modifications in nonpregnant adults with overweight or obesity in outpatient settings: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2026. doi:10.7326/ANNALS-25-02714.